Abstract
Little information exists on how constantly growing pharmaceutical expenditures are distributed in large representative samples of national populations in Western countries. This study analyzes the distribution of pharmaceutical expenditures in ambulatory care and explores the basic characteristics of the high-cost drug users. Reimbursed prescription drug purchases in 2009 were derived from the National Prescription Register for a 50% sample of the adult Finnish population. The high-cost users who were among the top 5% in terms of drug expenditures were identified based on annual drug costs. The distribution of pharmaceutical costs is strongly skewed in Finland; only 5% of the population accounts for about half of the costs. These high-cost drug users were older than the low-cost drug users, with more than one-fourth of them being over 75 years old. The high-cost drug users used, on average, more drugs than the low-cost drug users, but approximately 15% of them used only 1-5 drugs. Almost 50% of the high-cost drug users used more than 10 drugs per year. They had chronic diseases more often than the low-cost drug users, especially uremia requiring dialysis, post-transplant conditions, severe anemia associated with chronic renal ...Continue Reading
References
Oct 1, 1989·Scandinavian Journal of Primary Health Care·D Isacson, B Haglund
Jan 1, 1994·European Journal of Clinical Pharmacology·J Hallas, A Nissen
Mar 23, 2001·Health Affairs·M L Berk, A C Monheit
Sep 18, 2001·Health Affairs·C P ThomasS S Wallack
Jan 8, 2003·PharmacoEconomics·Silvia M EssThomas D Szucs
Feb 26, 2004·BMJ : British Medical Journal·Sebastian SchneeweissJerry Avorn
Apr 21, 2006·The Cochrane Database of Systematic Reviews·M AaserudH Sturm
May 12, 2006·Journal of the American Geriatrics Society·Masafumi KuzuyaAkihisa Iguchi
Jul 26, 2006·Pharmacotherapy·J Alexander ColeAlexander M Walker
Jan 11, 2007·Health Affairs·Samuel H Zuvekas, Joel W Cohen
Apr 20, 2007·British Journal of Clinical Pharmacology·Solveig SakshaugSvetlana Skurtveit
Aug 23, 2007·European Journal of Clinical Pharmacology·Jari HaukkaJouko Lönnqvist
Feb 7, 2008·The Cochrane Database of Systematic Reviews·A Austvoll-DahlgrenA Vernby
Jun 14, 2008·Pharmacy World & Science : PWS·Jean-Marc KrähenbühlOlivier Bugnon
Mar 10, 2009·The International Journal on Drug Policy·Norbert ScherbaumBaerbel Marrziniak
Apr 28, 2009·Clinical Therapeutics·Jaana E Martikainen, Hannes Enlund
Jul 14, 2009·Drugs & Aging·Johanna JyrkkäSirpa Hartikainen
Aug 25, 2009·Clinical Therapeutics·Hanna KoskinenTimo Maljanen
Nov 26, 2009·Drugs & Aging·Johanna JyrkkäSirpa Hartikainen
Dec 8, 2009·Basic & Clinical Pharmacology & Toxicology·Kari FuruHenrik Toft Sørensen
Mar 17, 2010·The American Journal of Geriatric Pharmacotherapy·Lisa L DwyerElizabeth A Rechtsteiner
Apr 3, 2010·Drugs & Aging·Maria RikalaMaarit Jaana Korhonen
Apr 26, 2011·Health Policy·Bo HovstadiusGöran Petersson
May 12, 2011·British Journal of Clinical Pharmacology·Chirn-Bin ChangDing-Cheng Derrick Chan
Citations
Nov 3, 2015·Expert Review of Pharmacoeconomics & Outcomes Research·Tkt LoJulie Byles
Mar 3, 2015·Pharmacoepidemiology and Drug Safety·Leena K Saastamoinen, Jouko Verho
Apr 29, 2015·European Journal of Clinical Pharmacology·Anita ØymoenAnna Birna Almarsdóttir
Feb 11, 2014·Health Policy·David Vivas-ConsueloLaia Buigues-Pastor
Jul 14, 2018·Basic & Clinical Pharmacology & Toxicology·Virva HyttinenHannu Valtonen
Feb 17, 2018·Cost Effectiveness and Resource Allocation : C/E·O HirschN Donner-Banzhoff
Apr 19, 2016·Health Services Research·Deirdre WeymannSteven G Morgan
Jul 20, 2019·Annals of Medicine·Joosep KalamägiAnna-Maija Tolppanen